Veracyte Says Decipher Test Predicts Abiraterone Benefit in High-Risk Prostate Cancer

Veracyte said a Phase III STAMPEDE study analysis found its Decipher Prostate test can predict benefit from adding abiraterone in clinically very high-risk, nonmetastatic prostate cancer. The analysis is to be presented at ESMO.